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Abstract The c-myb proto-oncogeneproduct (c-Myb) is a 
transcriptional regulator that binds to the specific DNA 
sequence. Deletion of the negative regulatory domain (NRD) in 
the carboxyl-proximal region of c-Myb results in both increased 
fnww-activating capacity and oncogenic activation. One possible 
mechanism to modulate c-Myb activity is a regulation of DNA-
binding activity. However, it is not known whether any region in 
NRD affects the in vivo DNA-binding activity of c-Myb. Using 
the highly transfectable cell line 293T, we developed a system to 
precisely measure the DNA-binding activity of Myb expressed in 
mammalian cells. Using this system, two regions in NRD were 
shown to repress DNA-binding activity. These results suggest 
that DNA-binding activity of c-Myb is independently regulated 
by multiple mechanisms through these subdomains. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The myb gene was originally identified as an oncogene car-
ried by the chicken retroviruses, avian myeloblastosis virus 
(AMV) and E26 [1,2], that transform myelomonocytic hema-
topoietic cells [for review, see [3]]. Homozygous c-myb mutant 
mice are severely anemic and die in utero due to defective fetal 
hematopoiesis [4], indicating that the myb gene product (Myb) 
plays a critical role in the development of a normal hemato-
poietic system. c-Myb is a transcriptional regulator that binds 
to the specific DNA sequences, 5'-AACNG-3' [5-8]. 
The c-myb proto-oncogene has no transforming capacity 
[9-11], but v-myb carried by AMV or E26 can transform 
myelomonocytic cells [2,3]. Comparison of c-Myb with the 
oncogenically activated forms indicated that a carboxyl (C)-
terminal truncation induces oncogenic activation. c-Myb has 
three functional domains responsible for DNA-binding, tran-
scriptional activation, and negative regulation (in that order) 
from the N-terminus [12]. The negative regulatory domain 
(NRD) normally represses c-Myb activity, and removal of 
this domain results in increased /raws-activating capacity and 
oncogenic activation [10,12]. NRD contains the leucine zipper 
motif, and disruption of this leucine zipper increases both the 
^raws-activating and transforming capacities of c-Myb, sug-
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gesting that the putative inhibitor represses the c-Myb activity 
by binding to c-Myb through this leucine zipper [13]. 
The DNA-binding domain of c-Myb is located within the 
N-terminal region, and consists of three imperfect tandem 
repeats of 51-52 amino acids (Rl, 2, and 3 from the N-termi-
nus) [12]. R3 and R2 cooperatively recognize the AACNG 
sequence, while Rl is not involved in the sequence recogni-
tion, but increases the stability of the Myb-DNA complex 
[14,15]. Structure analyses indicated that both R3 and R2 
contain three helices and that the third helix in each is a 
recognition helix. The C-truncated form of c-Myb that lacks 
NRD has a higher DNA-binding activity than the full-length 
form [16], suggesting that NRD represses the DNA-binding 
activity. To identify the mechanism of oncogenic activation of 
c-myb, it is important to find any uncharacterized subdo-
main(s) in NRD and to discover how they repress c-Myb 
activity. However, it has not been found which region(s) in 
NRD represses DNA-binding activity. This was mainly due to 
the lack of an assay system to precisely measure the DNA-
binding activity of various forms of c-Myb. 
Electrophoretic mobility shift assay (EMSA) using nuclear 
extracts prepared from culture cells transfected by the c-Myb 
expression plasmid, is one method for examining the DNA-
binding activities of various forms of c-Myb. In fact, mam-
malian cells such as NIH 3T3 cells transfected with the Myb 
expression plasmid expressed some Myb, judged by Western 
blotting. Using EMSA with nuclear extracts prepared from 
these transfected cells, however, only a very low level of 
DNA-binding activity of c-Myb was detected (data not 
shown). This could be due to the low level of expression 
and lability of Myb in transfected cells. 
In this study, using the highly transfectable 293T cell line, 
we have developed a system to measure the DNA-binding 
activities of various forms of Myb. Using this system, two 
subdomains that repress the DNA-binding activity have 
been identified in NRD. 
2. Materials and methods 
2.1. Plasmid construction 
All plasmids to express wild-type c-Myb and C-terminal truncated 
mutants CT1, CT2, and CT3 have been described [12]. The three 
plasmids to express mutants CTY, CTX, and CTV are truncated at 
amino acids 460, 448, and 435, respectively [10]. To construct the 
C-terminal truncated mutant CT471, termination codons were intro-
duced at nucleotide 1450 (nucleotide numbers are as in [17]) by the 
polymerase chain reaction method. In the CT372 expression plasmid, 
the G-residue at 1155 was deleted, so a frameshift was produced and a 
termination codon was introduced 2 codons past this 1-bp deletion. 
To construct all internal deletion mutants, the oligonucleotide con-
taining sequences on either side of the amino acids to be deleted were 
synthesized and used. This resulted in an in-frame deletion of the 
entire region of interest. 
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2.2. DNA transfection and preparation of nuclear extracts 
The 293T cell line was derived from the adenovirus type 5-trans-
formed human embryonic kidney 293 cell line, and contains the sim-
ian virus 40 large tumor antigen [18]. 293T cells were grown in Dul-
becco's modified Eagle's medium containing 10% fetal bovine serum. 
On the day before transfection, 1.4 X 106 293T cells were plated onto 
6-cm plastic tissue culture dishes, and left to adhere overnight. Four 
hours after a medium change, 10 ug of the plasmid DNA to express 
various forms of Myb was added to cells in the form of a calcium 
phosphate precipitate, and the cells were placed in an incubator for 4 h 
to permit the uptake of the DNA-CaPC>4 precipitate. The cells were 
then trypsinized and replated onto a 10-cm dish. Forty to 48 h after 
transfection, nuclear extracts were prepared as described by Dignam 
et al. [19]. 
2.3. Western blot analysis 
Nuclear extracts, which were prepared from 293T cells transfected 
with plasmids encoding c-Myb mutants, were separated by SDS-
PAGE on 10% gels and then transferred to nitrocellulose filters. 
The c-Myb proteins were detected by sequential binding of the anti-
c-Myb monoclonal antibody 5.1 [20], horseradish peroxidase-labeled 
anti-mouse antibody, and enhanced chemiluminescense (ECL) West-
ern blotting detection reagents (Amersham). To precisely measure the 
relative amount of c-Myb, a series of diluted protein samples were 
used for Western blot analyses, and the densities of protein signals 
were measured by a Bioimage analyzer (Milligen Biosearch). 
2.4. EMS A 
The nuclear extracts containing various forms of c-Myb were in-
cubated for 15 min at 25°C with 1 ng of 32P-labeled MBS-I oligonu-
cleotide probe in 20 ul of binding buffer (25 mM HEPES, pH 7.9, 
0.5 mM EDTA, 10 mM dithiothreitol), containing 2 |xg poly(dl-dC), 
200 ug bovine serum albumin, 1 ug calf thymus single-stranded DNA, 
and 0.1 |Xg mutant MBS-I(9C->T) oligonucleotide. The reaction mix-
ture was then put onto a 4% polyacrylamide gel in 0.25 X TBE (22.25 
mM Trizma base, 22.25 mM boric acid, 0.5 mM EDTA) and electro-
phoresed. The amount of nuclear extract used for EMSAs was ad-
justed based on the result of Western blotting, and the difference in 
the amount of total protein was within 2-fold between each reaction. 
For the competition analysis, varying amounts of cold competitor 
oligonucleotide were mixed with 32P-labeled MBS-I probe and bind-
ing reactions were done as described above. For supershift analysis, 
the anti-c-Myb monoclonal antibody 1.1 or 5.1 [20] was added to the 
reaction mixture. The radioactivity of the Myb-DNA complex was 
measured using a Bioimage analyzer (Fuji). 
3. Results 
3.1. EMSAs by using nuclear extracts containing 
authentic c-Myb 
Nuclear extracts prepared from 293T cells transfected with 
the wild-type c-Myb expression plasmid or from untransfected 
293T cells as a control were used for EMSAs with the DNA 
probe containing the Myb-binding site, MBS-I (Fig. 1A). Two 
retarded bands (marked by asterisks in Fig. 1A) were ob-
served with the control nuclear extracts, while nuclear extracts 
containing c-Myb generated two additional bands (marked by 
arrows in Fig. 1A) (Fig. 1A, lanes 1 and 2). Addition of the 
Myb-specific monoclonal antibody 1-1, of which the epitope is 
located in NRD, supershifted the upper additional band (the 
supershifted band is like a smear and is not visible) (Fig. 1A, 
lane 3). Addition of another antibody, 5-1, of which the epit-
ope is located in the transcriptional activation domain 
blocked the generation of two additional bands (Fig. 1A, 
lane 4). Since the transcriptional activation domain is next 
to the DNA-binding domain, the antibody 5-1 may inhibit 
the DNA binding of Myb by masking the DNA-binding do-
main. These results indicate that the upper and lower bands 
are generated by full-length c-Myb and the degraded c-Myb 
lacking C-proximal portion, respectively. 
All of the four retarded bands were competed with by the 
addition of a 50-fold molar excess of the MBS-I competitor 
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Fig. 1. Sequence-specific DNA-binding by authentic c-Myb. A: EMSAs. EMSAs were done with nuclear extracts from control 293T cells 
(lane 1) or 293T cells transfected with the c-Myb expression plasmid (lanes 2-10) and the 32P-labeled oligonucleotide MBS-I. Lanes 3,4: Myb-
specific monoclonal antibodies 1-1 and 5-1 were added, respectively. Lanes 5-9: The indicated amount of cold DNA competitor containing 
MBS-I site was added in the amounts shown at the top. Lane 10: 100 ng of cold DNA competitor MBS-I(9C->T) was added. The Myb-
DNA complexes are indicated by arrows. The upper and lower arrows show the complexes generated by full-length and degraded c-Myb, re-
spectively. Two bands indicated by asterisks were generated by proteins other than c-Myb. B: DNA sequence of the MBS-I probe and the 
MBS-I(9C->T) competitor. The consensus sequence AACNG recognized by c-Myb is boxed. 
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Fig. 2. Carboxyl truncation of Myb increases DNA-binding activity. A: Structures of C-truncated mutants used. The three functional domains 
of mouse c-Myb are shown at the top. The relative DNA-binding activity of each mutants measured by EMSAs in (C) is indicated on the 
right. B: Immunodetection of c-Myb mutants in transfected cells. Nuclear extracts were prepared from 293T cells transfected with plasmids en-
coding the c-Myb mutants shown above each lane or control 293T cells without transfection (lane 7). After separation by SDS-PAGE on a 
10% gel, c-Myb proteins were detected by Western blotting. To precisely measure the relative amounts of c-Myb, a series of diluted samples 
were used for Western blotting. Here, typical results obtained with the appropriate amounts of protein are shown. The 97-kDa band above the 
full-length c-Myb band is the non-specific band generated by the 293T cell lysates. C: EMSAs. The MBS-I probe was incubated with nuclear 
extracts used in (B) in the presence of 100 ng of the mutants MBS-I(9C->T) oligonucleotide. Amounts of nuclear extracts used was normalized 
by the results of Western blotting to have an equal amounts of c-Myb proteins. 
(Fig. 1A, lanes 5-9), indicating that two bands observed with 
293T control extracts are also generated by specific binding of 
some proteins to the MBS-I probe. Since these two bands may 
disturb the analyses of Myb-DNA complex formed by vari-
ous length of Myb, we tried to block the formation of these 
two bands by addition of an appropriate oligonucleotide com-
petitor. We had used various oligonucleotides to analyze the 
effects on Myb binding to point mutations in MBS-I [21]. A 
series of oligonucleotides used in that study were added to the 
reactions of EMSAs, and one oligonucleotide MBS-I(9C -> T) 
was found to block the generation of two retarded bands 
observed with the control 293T extracts, but not that of two 
other bands containing Myb (Fig. 1A, lane 10). In the oligo-
nucleotide MBS-I(9C^T), the third C residue in the Myb-
recognition sequence AACNG was changed to T (Fig. IB), 
and Myb cannot bind to this oligonucleotide. These results 
indicate that the proteins that are involved in the two bands 
observed with the 293T control extract are not endogenous 
c-Myb of 293T cells. Thus, by addition of a specific oligonu-
cleotide as a competitor, the EMSAs suitable to measure the 
DNA-binding activity of various forms of Myb have been 
developed. 
3.2. Presence of two subdomains 
To identify the subdomain(s) in NRD that repress the 
DNA-binding activity, we have examined the effects of C-ter-
minal truncation on DNA-binding activity by using the sys-
tem described above. The expression vectors for a series of 
C-terminal truncated mutants were constructed (Fig. 2A), and 
transfected into 293T cells. Nuclear extracts were prepared 
from transfected cells, and amounts of c-Myb in each prepa-
ration of nuclear extracts were measured by Western blotting 
using a series of diluted extracts (Fig. 2B). The EMSAs were 
done using the normalized amounts of nuclear extracts based 
on the results of Western blotting to have an almost equal 
amount of c-Myb (Fig. 2C). Deletion of the C-terminal 136-
amino-acid region (CT1) did not affect the DNA-binding ac-
tivity, indicating that the region downstream of NRD does 
not regulate the DNA-binding activity. Truncation to amino 
acid 435 (CTV) increased DNA-binding activity 3.8-fold. Fur-
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Fig. 3. Identification of the C-proximal subdomain, NRD2. A: Structures of truncated and internal deletion mutants used. The results of 
EMSAs shown in (C) are summarized on the right. ATP is a mutant lacking the putative phosphorylation site for proline-dependent kinase be-
tween amino acids 472 and 500. B: Immunodetection of c-Myb mutants in transfected cells. C: EMSAs. The experiments in (B,C) were done 
and the results are shown as in Fig. 2. 
ther truncation to amino acid 400 (CT2) or 372 (CT372) 
slightly increased DNA-binding activity compared with 
CTV, but this increase was not significant. However, further 
truncation to amino acid 325 (CT3) significantly increased 
DNA-binding activity (9-fold) compared with CTV. Thus, 
two regions in NRD, amino acids 435-500 (C-proximal sub-
domain: NRD2) and 325-372 (N-proximal subdomain: 
NRD1), appear to negatively regulate the DNA-binding ac-
tivity of c-Myb. 
3.3. Identification of the C-proximal subdomain, NRD2 
To further narrow down the C-proximal subdomain, we 
made three additional constructs to express CT471, CTY, 
and CTX, and examined their DNA-binding activities. 
DNA-binding activities of all three mutants were higher by 
about 3-fold than that of wild type (data not shown), suggest-
ing the region that represses DNA-binding activity is between 
amino acids 471 and 500. To confirm that this region really 
represses DNA-binding activity, we made a expression vector 
for an internal deletion mutant lacking this region (A472-500) 
(Fig. 3). This mutant had 3-fold higher DNA-binding activity 
than wild type, indicating that the C-proximal subdomain 
designated as NRD2 is in this region. In addition, a small 
deletion of the region next to this subdomain (A456-471) did 
not affect the DNA-binding activity. Therefore, to repress 
DNA-binding activity, a further N-proximal region is not 
required, suggesting that the region between amino acids 
471-500 is sufficient for negative regulation of DNA binding. 
In this region, the putative phosphorylation site by proline-
dependent protein kinase or MAP kinase (484 PQTPSHAV 
491) is located. However, deletion of this putative phospho-
rylation site, the TP residue at amino acids 486 and 487, 
(ATP) did not affect the DNA-binding activity (Fig. 3). 
3.4. Identification of the N-proximal subdomain, NRD1 
We next tried to narrow down the N-proximal subdomain 
(Fig. 4). The results in Fig. 1 indicate that the region between 
amino acids 325 and 372 is critical for negative regulation of 
DNA-binding activity. To confirm this result, we constructed 
an internal deletion mutant lacking this region (A326-372) and 
examined its DNA-binding activity by EMSAs. This mutant 
had 3.4-fold higher DNA-binding activity than wild type. 
Then, two mutants lacking either the N- or C-terminal half 
(A326-349 and A350-372) of this region were made, and their 
DNA-binding activities were examined. Both of them had al-
most the same activity as wild type. These results indicate that 
deletion of the whole region between amino acids 326 and 372 
is necessary to increase DNA-binding activity. This N-prox-
imal subdomain was designated as NRD1. 
3.5. Role of leucine zipper, NRD1, and NRD2 in 
DNA binding of c-Myb 
We have examined the effects of the leucine zipper mutation 
on the DNA-binding activity of authentic c-Myb using the 
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293T cell system. The results of EMSAs indicated that the 
DNA-binding activity of the leucine zipper mutant L34P 
was almost the same as that of wild type (Fig. 5). To further 
confirm whether NRD contains only two subdomains (NRDl 
and NRD2) in addition to the leucine zipper, a mutant 
(ANRD1+2) that internally lacks both subdomains were con-
structed and its DNA-binding activity was examined (Fig. 5). 
The DNA-binding activity of ANRD1+2 was comparable to 
that of CT3 lacking the whole region of NRD. These results 
confirm that the critical subdomains that negatively regulate 
the DNA-binding activity of the authentic c-Myb are NRDl 
and NRD2. 
4. Discussion 
Using the chicken cell line, two groups reported analyses of 
the DNA-binding activity of c-Myb expressed in virus-in-
fected or plasmid-transfected cells [22,23]. However, it seemed 
to be difficult to analyze the DNA-binding activity of various 
forms of c-Myb precisely using these systems due to the pres-
ence of degraded products of c-Myb. In the present study 
using the 293T cell system, we have identified two subdomains 
in NRD, NRDl and NRD2, that negatively regulate DNA-
binding activity of c-Myb (Fig. 6A). The N-proximal subdo-
main, NRDl , contains two putative phosphorylation sites by 
proline-dependent kinase or MAP kinase, one site by glycogen 
synthetase kinase-3, and one site by casein kinase II (Fig. 6B). 
The C-proximal subdomain, NRD2, also contains one puta-
tive phosphorylation site for proline-dependent kinase (Fig. 
6B). However, phosphorylation at this site in NRD2 is prob-
ably not critical for regulation of DNA-binding activity, since 
deletion of this putative phosphorylation site did not affect the 
DNA-binding activity. At present, it is not known whether the 
conformation of these regions, or the modification of c-Myb 
by the factor(s) such as phosphorylation, is important for 
regulation of DNA-binding activity. 
Krieg et al. expressed full-length c-Myb in HeLa cells using 
a recombinant vaccinia virus, and found that the purified full-
length c-Myb binds to DNA with almost the same affinity as 
the protein containing the DNA-binding domain alone [24]. 
This indicates that a deletion of the C-terminal region does 
not increase the DNA-binding activity, and is inconsistent 
with our results. However, the significant difference between 
their system and ours is that our EMSA used the crude nu-
clear extract, not the purified c-Myb. Since the reaction for 
DNA binding in our system contains many factors, some 
factor(s) may regulate the DNA-binding activity by binding 
to NRDl and NRD2. 
Using the bacterially made c-Myb that lacks the down-
stream region from the leucine zipper, we had demonstrated 
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that the leucine zipper mutant had 3^-fold higher DNA-
binding activity than wild type [25]. In the 293T cell system 
described here, however, the DNA-binding activity of the leu-
cine zipper mutant was almost the same as that of wild type. 
Since the effect of the leucine zipper mutations on the trans-
activating capacity of c-Myb varies between the cells used [13], 
the effects of the leucine zipper mutation on DNA-binding 
activity could also depend on the cells used. 
The v-Myb encoded by AMV lacks NRD2, and the v-Myb 
encoded by E26 lacks NRD2, the leucine zipper motif, and 
the half of NRDl (Fig. 6A). So far, transforming capacities of 
various C-truncated forms of Myb were examined by using 
the mouse [9,10] and chicken [11] systems. In both systems, 
removal of the whole region of NRD dramatically increased 
transforming activity, and truncation of the region containing 
NRD2 identified in this study (CTY construct in the mouse 
system) slightly but significantly increased transforming ca-
pacity. Disruption of the leucine zipper motif also resulted 
in oncogenic activation in mouse system [13], but the effects 
of the leucine zipper disruption on transforming activity were 
not examined in the chicken system. It was also not examined 
whether deletion of NRDl induces oncogenic activation in 
mouse and chicken system. Presence of multiple subdomains 
that negatively regulate c-Myb activity suggest that c-Myb 
activity is regulated multiple mechanisms and oncogenic acti-
vation is also induced by multiple mechanisms. 
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are indicated by arrows. B: The amino acid sequence of NRDl and NRD2. The putative phosphorylation sites by proline-dependent kinase, 
glycogen synthetase kinase III, and casein kinase II are indicated by single, double, and dotted underlines, respectively. 
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